Human CA19-9(CarbohydRate antigen19-9) ELISA Kit

Carbohydrate antigen 19-9 (CA 19-9) is widely recognized as a biomarker for pancreatic cancer and various gastrointestinal malignancies. Since it was first identified by Koprowski et al. in colorectal cancer cell lines in 1979, CA 19-9 has become an essential tool for diagnosing and assessing the prognosis of pancreatic ductal adenocarcinoma (PDAC). Its role in managing malignancies such as pancreatic and biliary cancers has solidified its importance, particularly in screening, staging, treatment monitoring, and predicting recurrence in pancreatic diseases. From a structural perspective, CA 19-9 is basically a sialylated Lewis antigen (sialyl Lewis a, sLe a). β1,3-galactosyltransferase, α(2,3)-sialyltransferase, and fucosyltransferase (FUT3) are some of the important enzymes involved in its manufacture. The specificity of CA 19-9 as a diagnostic for particular illnesses is guaranteed by this intricate biosynthesis route. Though higher levels can also be seen in fetal tissues, normal gastrointestinal epithelial cells, and a number of benign disorders, it is crucial to remember that CA 19-9 is not very tumor-specific. The sensitivity of CA 19-9 as a pancreatic cancer marker is about 80%. However, because of its low sensitivity and specificity, it is not appropriate as a stand-alone screening method, particularly for early-stage pancreatic cancer. According to research, CA 19-9 levels over the usual cutoff of 37–40 U/mL are diagnostically significant, albeit they can also be raised in 10%–50% of people with benign pancreatic diseases such pancreatitis. Therefore, CA 19-9's main function in the diagnosis of pancreatic cancer is to support imaging tests, as those carried out with pancreatic protocol CT scans.

In pancreatic cancer staging and management, CA 19-9 levels generally correlate with tumor burden. Studies have found that median preoperative CA 19-9 levels positively correlate with tumor size and pathological staging. For example, one study revealed that patients with stage III-IV PDAC typically had CA 19-9 levels exceeding 100 U/mL, whereas those with T1/2-stage lesions had relatively lower levels. Elevated CA 19-9 not only aids in determining tumor staging but also helps guide the feasibility of surgical resection. In PDAC surgery, significantly elevated preoperative CA 19-9 levels often indicate unrespectability, sparing patients from undergoing unnecessary exploratory surgeries.CA 19-9 is commonly utilized for postoperative surveillance in addition to respectability assessments. According to research, stabilization or a decreasing trend in CA 19-9 levels following surgery is associated with a better prognosis, but persistently elevated levels may indicate concealed recurrence or residual disease.This makes CA 19-9 a significant predictor of pancreatic cancer recurrence. Several studies have found that rising CA 19-9 levels typically precede radiographic evidence of recurrence, sometimes by as much as 2 to 6 months, emphasizing their potential value in early detection of recurrence following pancreatic surgery.

Although CA 19-9 is widely used to treat pancreatic cancer, its benefits go beyond this condition. CA 19-9 has also demonstrated diagnostic and prognostic use in other gastrointestinal malignancies. For example, people with colorectal cancer who have higher CA 19-9 levels typically have worse prognosis. Likewise, increased CA 19-9 is seen as a sign of advanced or metastatic gastric cancer. Additionally, CA 19-9 has been used in various other malignancies, including hepatocellular carcinoma, cholangiocarcinoma, esophageal cancer, gynecological cancers, and urological cancers. However, the application of CA 19-9 as a cancer biomarker comes with certain limitations. One major issue is the variability in test results across different laboratories, as different assays use various monoclonal antibodies, making direct comparisons challenging. Furthermore, benign diseases such pancreatitis, liver cirrhosis, cystic tumors, and biliary obstruction can also have increased CA 19-9 levels in addition to malignant tumors. The accuracy of CA 19-9 in cancer diagnosis may be hampered by certain benign diseases. Clinically, doctors must evaluate CA 19-9 levels in combination with clinical symptoms and other diagnostic instruments because relying just on this marker could result in a misdiagnosis. With the development of medical technology, CA 19-9's potential uses keep growing. According to recent studies, CA 19-9 may be a viable therapeutic target in addition to being a diagnostic and prognostic marker for pancreatic cancer and other cancers. Moreover, CA 19-9's role in non-malignant diseases like acute pancreatitis has also sparked the interest of researchers. Future research is expected to offer further insight on the precise mechanisms by which CA 19-9 acts in diverse disease processes, giving a theoretical foundation for the development of new diagnostic procedures and therapeutic approaches. To summarize, carbohydrate antigen 19-9 is an important biomarker for pancreatic cancer and other malignancies, with numerous clinical applications. Despite certain limits in sensitivity and specificity, CA 19-9 is an unquestionable tool for pancreatic cancer screening, diagnosis, therapy monitoring, and recurrence prediction. As research advances, the use of CA 19-9 is likely to extend further, providing more precise diagnostic and therapeutic options for controlling a wide range of disorders.

CA19-9 ELISA kit
Carbohydrate antigen 19-9 ELISA
Human CA19-9 detection kit